---
figid: PMC6172014__CAS-109-3024-g001
figtitle: Fibroblast growth factor receptor (FGFR) structure, FGFR signaling, and
  specificity of the FGF–FGFR interaction
organisms:
- Homo sapiens
- Macaca fascicularis
- Mus musculus
- Gallus gallus
- NA
organisms_ner:
- Mus musculus
- Gallus gallus
- Macaca fascicularis
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC6172014
filename: CAS-109-3024-g001.jpg
figlink: /pmc/articles/PMC6172014/figure/cas13759-fig-0001/
number: F1
caption: Fibroblast growth factor receptor (FGFR) structure, FGFR signaling, and specificity
  of the FGF–FGFR interaction. A, FGFR consist of an extracellular domain that contains
  3 immunoglobulin domains (D1‐D3), a transmembrane domain, and an intracellular tyrosine
  kinase domain. B, The formation of a 2:2:2 FGFR‐FGF‐heparan sulfate proteoglycan
  (HSPG) complex results in receptor dimerization and transphosphorylation at several
  tyrosine residues in the intracellular portion of FGFR. Activated FGFR causes the
  activation of the RAS–RAF–MAPK and PI3K‐AKT signaling pathway. Some other signaling
  pathways can also be activated by FGFR, including signal transducer and activator
  of transcription (STAT)‐dependent signaling. Several negative regulators are involved
  in FGFR signaling, such as SPRY and MKP3. C, Specificity of FGF ligands for FGFR‐IIIb
  and FGFR‐IIIc isoforms. DAG, diacylglycerol; PIP2, phosphatidylinositol‐4,5‐biphosphate;
  PIP3, phosphatidylinositol‐3,4,5‐triphosphate; PLCγ, phospholipase γ; SPRY, sprouty
papertitle: Role of fibroblast growth factor receptor 4 in cancer.
reftext: Shuya Tang, et al. Cancer Sci. 2018 Oct;109(10):3024-3031.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.939155
figid_alias: PMC6172014__F1
figtype: Figure
redirect_from: /figures/PMC6172014__F1
ndex: 1f09b53a-dedd-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6172014__CAS-109-3024-g001.html
  '@type': Dataset
  description: Fibroblast growth factor receptor (FGFR) structure, FGFR signaling,
    and specificity of the FGF–FGFR interaction. A, FGFR consist of an extracellular
    domain that contains 3 immunoglobulin domains (D1‐D3), a transmembrane domain,
    and an intracellular tyrosine kinase domain. B, The formation of a 2:2:2 FGFR‐FGF‐heparan
    sulfate proteoglycan (HSPG) complex results in receptor dimerization and transphosphorylation
    at several tyrosine residues in the intracellular portion of FGFR. Activated FGFR
    causes the activation of the RAS–RAF–MAPK and PI3K‐AKT signaling pathway. Some
    other signaling pathways can also be activated by FGFR, including signal transducer
    and activator of transcription (STAT)‐dependent signaling. Several negative regulators
    are involved in FGFR signaling, such as SPRY and MKP3. C, Specificity of FGF ligands
    for FGFR‐IIIb and FGFR‐IIIc isoforms. DAG, diacylglycerol; PIP2, phosphatidylinositol‐4,5‐biphosphate;
    PIP3, phosphatidylinositol‐3,4,5‐triphosphate; PLCγ, phospholipase γ; SPRY, sprouty
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Cxcl13
  - Mir155hg
  - Frs2
  - Grb2
  - ras
  - Hras
  - Kras
  - Rem1
  - Zhx2
  - Sta
  - Emd
  - Dusp6
  - Hspg2
  - Akt1
  - pc
  - pk
  - Fgfr2
  - Fgfr1
  - Il1b
  - Fgfr3
  - Atp9b
  - Fgfr4
  - Mdk
  - MIR155HG
  - FRS2
  - GRB2
  - PC
  - FGF10
  - FGFR2
  - FGFR1
  - IL1B
  - FGFR3
  - FGFR4
  - FGFRL1
  - CXCL13
  - SPRY1
  - SPRY2
  - SPRY3
  - SPRY4
  - XYLT2
  - SOS1
  - SOS2
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - PIK3CG
  - EMD
  - GCY
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - DUSP6
  - PLCG1
  - PLCG2
  - HSPG2
  - PLCE1
  - PLCZ1
  - PLCB1
  - PLCB2
  - PLCB3
  - PLCB4
  - PLCD1
  - PLCD3
  - PLCD4
  - AKT1
  - AKT2
  - AKT3
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - FGF1
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - btl
  - htl
  - Gclm
  - blc
  - bic
  - bcd
  - drk
  - sty
  - Sos
  - Ras64B
  - Ras85D
  - Raf
  - sta
  - MKP-4
  - p38b
  - rl
  - Mkp3
  - sl
  - norpA
  - Plc21C
  - Akt
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - bnl
  - E(Mer)IIb
  - Dsor1
  - Mtk
  - Tyrosine
  - Cancer
  - Cardiomyopathy
  - Kallmann syndrome
  - Noonan syndrome
---
